Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange

Articles

25
Show Summary
Show Bulletpoints
Detailed View
Bullish +65

Zimmer Biomet to pay up to $140M for Iovera nerve therapy

🤝 Zimmer Biomet acquires Iovera nerve therapy for up to $140 million.

💰 Deal includes $70M upfront plus milestones through late 2031.

📅 Transaction projected to close in third quarter of 2026.

❄️ Iovera offers drug-free pain relief via cryoneurolysis for up to 90 days.

💊 Clinical data shows 45% opioid reduction over 12 weeks post-surgery.

🤝 Zimmer Biomet agrees to acquire Pacira's Iovera nerve therapy technology for a total value up to $140 million.

💰 The deal structure includes a $70 million upfront payment plus potential milestone payments through late 2031.

📅 The transaction is projected to close in the third quarter of 2026.

🧬 Zimmer Biomet will assume full rights for development, manufacturing, and commercialization of Iovera.

🤝 Pacira retains a portion of compensation contingent on successful registrational study completion and regulatory approval.

❄️ Iovera utilizes cryoneurolysis to provide drug-free pain relief by temporarily interrupting nerve signals.

🦵 The device is FDA-cleared for treating osteoarthritis knee pain with efficacy lasting up to 90 days.

💊 Clinical data indicates a 45% reduction in opioid consumption over 12 weeks post-surgery among patients.

📈 Pacira CEO Frank D. Lee cites the deal as advancing their transition into an innovative biopharmaceutical company.

🌍 The partnership aims to leverage Zimmer Biomet's global scale to expand patient access worldwide.

Bullish Signals
  • Deal value reaches up to $140 million.
  • Integrates FDA-cleared cryoneurolysis technology into orthopedic portfolio.
  • Validates Pacira BioSciences technology platform with major partner.
  • Reduces opioid consumption by 45%.
Bullish Signals
  • Zimmer Biomet secures a strategic asset in pain management with a total deal value reaching up to $140 million, including significant milestone potential.
  • The acquisition of Iovera allows Zimmer Biomet to integrate FDA-cleared cryoneurolysis technology into its existing orthopedic portfolio.
  • Pacira BioSciences achieves a strategic pivot toward biopharmaceuticals with a major partner in Zimmer Biomet, validating their technology platform.
  • Iovera demonstrates strong clinical efficacy with a 45% reduction in opioid consumption and significant improvements in knee function scores.
Somewhat Bullish +50

Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Unpacking its 6.02% ...

📈 Zimmer Biomet trades at $93.1 with $18.01B market cap.

📊 Revenue grew 9.30% with a forward P/E of 10.36.

💰 Dividend yield is 1.03% on a 24.87% payout ratio.

👍 Analysts rate it buy with a $98.70 price target.

🤖 Innovation focuses on ROSA Robot and ZBEdge Platform.

📈 Zimmer Biomet trades at $93.1 with a market cap of $18.01 billion, positioned above key moving averages indicating bullish momentum.

📊 The company reports robust revenue growth of 9.30% and maintains a forward P/E ratio of 10.36.

💰 Investors receive a dividend yield of 1.03% supported by a conservative 24.87% payout ratio.

👍 Analyst consensus is positive with 8 buy ratings and an average price target of $98.70.

🤖 Strategic focus on innovation includes the ROSA Robot and ZBEdge Platform for enhanced surgical outcomes.

📉 Technical indicators show an RSI of 55.68 and a MACD buy signal at 1.32 above the signal line.

🎯 Price targets range from $83.00 to $130.00, reflecting varying analyst views on future growth.

Bullish Signals
  • Revenue growth of 9.30% indicates successful market expansion.
  • Stock trades above 50-day and 200-day moving averages.
  • Analyst price target of $98.70 implies 6.02% upside.
  • Conservative dividend payout ratio of 24.87% ensures flexibility.
  • Advanced innovations like ROSA Robot lead market.
Bullish Signals
  • Zimmer Biomet demonstrates robust revenue growth of 9.30%, indicating successful market expansion in the competitive medical device industry.
  • The stock trades above both its 50-day and 200-day moving averages, suggesting healthy short-term bullish momentum.
  • Analysts provide a consensus average price target of $98.70, implying a potential upside of 6.02% from the current trading price.
  • The company maintains a conservative dividend payout ratio of 24.87%, ensuring financial flexibility while returning value to shareholders.
  • Zimmer Biomet solidifies its market leadership through advanced innovations like the ROSA Robot and ZBEdge Platform, leveraging AI for better surgical outcomes.
Somewhat Bullish +45

Zimmer Biomet with clear technical picture, shares between support and resistance - Ad-hoc-news.de

📈 Zimmer Biomet shares rose 3.43% to close near $90.57 on June 24, 2026.

💰 Market cap estimated at approximately $18.1 billion based on recent trading levels.

🛡️ Technical analysis shows support at $84.56 and resistance at $93.58 for the sector.

📊 Momentum indicators rank Zimmer Biomet 16th out of 204 peers with four buy signals.

🏥 Company specializes in orthopedic reconstruction, sports medicine, spine, and surgical technologies.

📈 Zimmer Biomet shares recently gained approximately 3.43% to close around $90.57 on June 24, 2026.

💰 The company's market capitalization is estimated near $18.1 billion based on recent trading levels.

🛡️ Technical analysis identifies a support zone at $84.56 and resistance at $93.58 for the healthcare equipment sector.

📊 Momentum indicators rank Zimmer Biomet 16th out of 204 peers with four buy signals versus one sell signal.

🏥 The company specializes in orthopedic reconstruction, sports medicine, spine, and surgical technologies.

📍 Key operations are anchored in Warsaw, Indiana, serving global hospital markets.

📅 No official earnings date has been scheduled for the upcoming period.

Bullish Signals
  • Stock gained 3.43% daily showing bullish momentum.
  • Four buy signals vs one sell signal.
  • Ranks 16th of 204 peers on momentum.
  • Shares stable within established trading band.
Risk Factors
  • Stock confined to defined support and resistance range.
  • One active sell signal among key indicators.
  • No official earnings date creates reporting uncertainty.
Bullish Signals
  • Stock recently posted a daily gain of roughly 3.43%, indicating short-term bullish momentum.
  • Momentum indicators assign a constructive technical picture with four buy signals against one sell signal.
  • Zimmer Biomet ranks 16th out of 204 stocks in its healthcare equipment peer group based on price momentum.
  • Shares remain anchored within an established trading band, providing stability for swing traders.
Risk Factors
  • Technical analysis shows the stock is currently confined to a defined range between support and resistance levels.
  • There is one active sell signal among key indicators and moving averages.
  • No official earnings date has been scheduled, creating uncertainty regarding upcoming financial reporting.
Slightly Bearish -10

ZBH (NYSE) insider sells 31,252 and 5,373 shares in May 2026 - Stock Titan

📉 Suketu Upadhyay sold 36,625 shares for $3.07 million in May 2026.

💰 Two separate transactions generated gross proceeds of $3.07 million total.

🏦 Fidelity Brokerage Services LLC handled the proposed resale activity.

⚖️ SEC accepted Form 144 filing on June 24, 2026.

🔒 Insider confirms no knowledge of material adverse information.

📉 Insider Suketu Upadhyay sold 31,252 shares of ZBH on May 12, 2026, generating $2,608,859.38 in gross proceeds.

💰 A second sale of 5,373 shares occurred on May 19, 2026, yielding $464,120.14 in total value.

📅 The filing references historical restricted stock vesting events totaling 4,560 shares from July 2023 and February 2024.

🏦 Fidelity Brokerage Services LLC is listed as the intermediary handling the proposed resale activity.

⚖️ The Form 144 filing was accepted by the SEC EDGAR system on June 24, 2026.

📊 Total reported sale volume for May 2026 equals 36,625 shares with combined proceeds of approximately $3.07 million.

🔒 The insider represents no knowledge of material adverse information regarding the issuer's current or prospective operations.

🏢 The transaction involves common stock listed on the NYSE under ticker ZBH.

Risk Factors
  • Insider selling may increase supply and pressure stock price.
  • Sale of 36,625 shares signals potential lack of confidence.
Risk Factors
  • 📉 Insider selling activity may increase short-term share supply, potentially exerting downward pressure on the stock price if demand does not absorb the volume.
  • 💸 The sale of 36,625 shares represents a significant reduction in insider holdings, which some investors interpret as a lack of confidence in near-term upside.
Slightly Bullish +15

Zimmer Biomet updates knee surgery partnership, shares under S&P 500 peer scrutiny - Ad-hoc-news.de

🏈 Dr. Elliot Pellman serves as a Zimmer Biomet consultant.

📊 Global leader in knee reconstruction with strong hip and trauma presence.

💰 Shares traded at $87.29 USD with an $18.5 billion market cap.

🤖 Growth driven by robotic surgery adoption and biologics revenue.

⚠️ Investors monitor US and European reimbursement regime exposure.

🏈 Zimmer Biomet confirms Dr. Elliot Pellman of the New York Jets serves as a consultant to the company in updated NFL Health and Safety Committee disclosures.

📊 The company maintains global leadership positions in knee reconstruction systems with significant market presence in hip, trauma, and sports medicine segments.

💰 As of June 22, 2026, Zimmer Biomet shares traded at $87.29 USD with a market capitalization of approximately $18.5 billion.

🔍 Analysts are weighing the company's earnings profile against S&P 500 peers like Stryker and Boston Scientific based on procedure volumes and pricing discipline.

🤖 Key growth drivers identified by brokers include the adoption of robotic-assisted surgery and revenue from biologics supporting bone healing.

⚠️ Investors are monitoring exposure to US and European reimbursement regimes as critical factors influencing forward guidance scenarios.

📈 Consensus models track free-cash-flow conversion and balance-sheet flexibility as primary valuation anchors for the orthopedics group.

Bullish Signals
  • Global leader in knee reconstruction systems with durable revenue.
  • Significant market presence in hip, trauma, and biologics.
  • Robotic-assisted surgery adoption drives future earnings growth potential.
  • Strong balance-sheet flexibility anchors positive valuation.
Risk Factors
  • Exposure to US/EU reimbursement regimes impacts forward guidance.
  • Competitive pressure from rivals like Stryker highlighted.
  • Uncertainty over near-term financial reporting timelines exists.
Bullish Signals
  • Zimmer Biomet holds a global leadership position in knee reconstruction systems, providing a durable revenue stream from its core product portfolio.
  • The company maintains a significant market presence in hip reconstruction, trauma implants, and biologics, diversifying its revenue sources beyond just knees.
  • Analysts identify the adoption of robotic-assisted surgery as a key earnings driver, suggesting potential for future growth in procedure volumes.
  • The company's balance-sheet flexibility is cited by investors as a positive valuation anchor, indicating financial resilience.
Risk Factors
  • Zimmer Biomet faces scrutiny regarding its exposure to US and European reimbursement regimes, which could impact forward guidance scenarios.
  • Analysts are actively comparing the company's earnings profile against rivals like Stryker, highlighting competitive pressure in the orthopedics sector.
  • The lack of an officially scheduled next earnings date introduces uncertainty regarding near-term financial reporting timelines.
Slightly Bullish +15

Zimmer Biomet Stock - Sunday background on business and valuation - Ad-hoc-news.de

🏢 Formed by 2015 merger, headquartered in Warsaw, Indiana.

💰 Stock at $88.00 with $17.02 billion market cap.

🦴 Hip and knee implants sold in over 100 countries.

⚠️ Risks include regulatory changes, litigation, and pricing pressure.

🏆 Competes with Stryker, J&J DePuy Synthes, and Smith+Nephew.

🏢 Zimmer Biomet is a top-tier orthopedic specialist formed by the 2015 merger of Zimmer and Biomet, headquartered in Warsaw, Indiana.

💰 As of June 18, 2026, the stock traded at $88.00 with a market cap of $17.02 billion on the New York Stock Exchange.

🌍 The company operates globally with significant revenue streams from the US, Europe, and Asia-Pacific markets.

🦴 Core products include hip and knee implants used in elective and trauma-related surgeries across more than 100 countries.

📉 Recent trading shows stability with modest gains over the past month but remains below its 52-week highs.

🛡️ The business model relies on recurring implant sales, digital tools, and strong relationships with surgeons and hospital systems.

⚖️ Management focuses on cost-control initiatives, footprint optimization, and supply-chain improvements to support operating margins.

🔬 R&D spending continues to fund new implant designs, materials, and regulatory approvals for expanding clinical indications.

📈 Cash flow is deployed toward capital expenditures, bolt-on acquisitions, dividends, and share repurchases.

⚠️ Key risks include regulatory changes, product quality issues, litigation exposures, and pricing pressure from hospital customers.

🏆 Competes in a concentrated landscape with peers like Stryker, Johnson & Johnson's DePuy Synthes, and Smith+Nephew.

🤖 Flagship offerings include the Persona knee replacement system tailored to individual patient anatomy and surgical preferences.

Bullish Signals
  • Core orthopedic name with balanced mature implant franchises.
  • Solid operating cash flow supports dividends and buybacks.
  • Diversified revenue base across US, Europe, and Asia-Pacific.
  • Reshaped portfolio to focus on higher-margin segments.
  • Capturing share in faster-growing subsegments like partial knees.
Risk Factors
  • Currency and regional trends hurt global growth and profitability.
  • Risks include regulation, quality issues, litigation, and pricing pressure.
  • Product recalls cause financial and reputational costs.
  • Competitors fight on innovation, outcomes, and service in concentrated market.
Bullish Signals
  • ZBH is a core name in orthopedic devices with a balanced portfolio of mature implant franchises and demonstrated cost discipline.
  • The company generates solid operating cash flow, providing financial flexibility for capital expenditures, bolt-on deals, dividends, and share repurchases.
  • Zimmer Biomet maintains a diversified geographic revenue base across the US, Europe, and key Asia-Pacific markets, reducing reliance on any single region.
  • Management has successfully reshaped the portfolio through divestitures and acquisitions to focus on higher-margin, innovation-driven segments.
  • The company is well-positioned to capture share in faster-growing subsegments such as partial knee replacements, revision surgeries, and outpatient procedures.
Risk Factors
  • Currency movements and regional procedure trends can negatively influence reported growth and profitability given the company's global operations.
  • Key risks include regulatory changes, product quality issues, litigation exposures, and pricing pressure from hospital customers and payers.
  • Product recalls or safety warnings in the medical-device sector can be financially and reputationally costly.
  • Competitive dynamics pose a risk as rival device makers compete on innovation, clinical outcomes, and service levels in a concentrated market.
Bullish +65

Is Zimmer Biomet’s US$1 Billion Buyback And Dividend Shift Altering The Investment Case For ZBH? - simplywall.st

📈 Zimmer Biomet expands buyback program to $1 billion for fiscal 2026.

💰 Company declares quarterly dividend of $0.24 per share.

📊 Strong results prompt management to raise forward guidance.

🔬 Growth strategy relies on robotics and implant technology adoption.

⚠️ Ongoing pricing pressure remains a key profitability risk.

📈 Zimmer Biomet announced an expanded share repurchase program of up to US$1.00 billion for fiscal 2026.

💰 The company declared a quarterly cash dividend of US$0.24 per share alongside the buyback initiative.

📊 Recent quarterly results exceeded expectations, prompting management to raise its forward guidance.

🔬 Long-term growth strategy relies on the successful adoption of new robotics and implant technologies.

⚠️ Ongoing pricing pressure remains a key risk factor that could impact future profitability.

🎯 Analyst fair value estimates for ZBH range widely from US$98.70 to US$207.48.

💼 Management is utilizing excess cash to return capital to shareholders while funding innovation.

Bullish Signals
  • Initiated US$1.00 billion share repurchase program for fiscal 2026.
  • Declared quarterly cash dividend of US$0.24 per share.
  • Recent results exceeded expectations with raised revenue and earnings guidance.
  • Disciplined capital allocation combining aggressive buybacks with dividends.
Risk Factors
  • Pricing pressure threatens future medical device margins.
  • Valuation divergence includes low estimates of US$98.70.
Bullish Signals
  • Zimmer Biomet has initiated a substantial US$1.00 billion share repurchase program for fiscal 2026, demonstrating strong confidence in its stock and financial stability.
  • The company declared a quarterly cash dividend of US$0.24 per share, providing consistent income to shareholders alongside the buyback.
  • Recent quarterly results exceeded analyst expectations, leading management to raise its forward guidance for revenue and earnings.
  • Management's decision to combine aggressive buybacks with dividends signals a disciplined approach to capital allocation and excess cash generation.
Risk Factors
  • The company faces ongoing pricing pressure in the medical device sector, which poses a risk to maintaining healthy future margins.
  • Analyst fair value estimates show significant divergence, with some valuations as low as US$98.70, suggesting potential overvaluation concerns for current holders.
Slightly Bullish +25

Is Zimmer Biomet Stock Underperforming the S&P 500? - Barchart.com

🏢 Zimmer Biomet leads orthopedic implants with $17.1B market cap.

📉 Stock slipped 18.2% from Aug 26, 2025 high of $108.29.

📊 Shares down 4.3% in three months vs S&P 500's 11.4% gain.

📈 Price recently crossed above 50-day moving average after March lows.

💰 Analysts rate 'Hold' with $98.24 target, a 10.9% premium.

🏢 Zimmer Biomet is a $17.1 billion market cap leader in orthopedic implants and digital solutions operating globally.

📉 Stock price has slipped 18.2% from its 52-week high of $108.29 achieved on Aug. 26, 2025.

📊 ZBH is down 4.3% over the past three months while the S&P 500 rose 11.4% during the same period.

📈 Shares recently climbed back above their 50-day moving average after trading below the 200-day average since March.

💰 Analysts hold a consensus 'Hold' rating with a mean price target of $98.24, a 10.9% premium to current prices.

🆚 The stock has outperformed peer Medtronic (MDT), which declined 16.5% on a YTD basis.

Bullish Signals
  • Operates in 100+ countries with broad implant portfolio.
  • Outperformed peer Medtronic (MDT) which declined significantly.
  • Shares climbed back above 50-day moving average.
  • Analyst target $98.24 suggests ~10.9% upside potential.
Risk Factors
  • Stock slipped 18.2% from 52-week high.
  • Concerns over sluggish growth and modest revenue.
  • Trailed S&P 500 with muted sales outlook.
Bullish Signals
  • The company operates in more than 100 countries with a broad portfolio of hip, knee, shoulder, and trauma implants.
  • ZBH has outperformed its major peer Medtronic (MDT), which has declined significantly over the past year.
  • Shares have recently shown signs of technical recovery by climbing back above the 50-day moving average.
  • The mean analyst price target of $98.24 suggests a potential upside of approximately 10.9% from current levels.
Risk Factors
  • The stock has slipped 18.2% from its 52-week high, indicating significant recent weakness.
  • Investors are growing concerned about the company's sluggish growth profile and modest revenue gains.
  • ZBH has trailed the S&P 500 Index significantly over the past year with a muted sales outlook.
Somewhat Bullish +50

Zimmer Biomet Holdings, Inc.: Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026

📅 Board approved $0.24 quarterly dividend on May 22, 2026.

💰 Payment scheduled for July 31, 2026 to record holders.

🏢 Global medical tech leader operating in 25+ countries.

📅 Zimmer Biomet Holdings, Inc. (NYSE/SIX: ZBH) announced on May 22, 2026, that its Board of Directors approved a quarterly cash dividend for the second quarter of 2026.

💰 The approved dividend amount is $0.24 per share to be paid to stockholders.

📅 The dividend payment date is scheduled for approximately July 31, 2026.

📋 Stockholders must be on record as of the close of business on June 25, 2026, to receive the payment.

🏢 Zimmer Biomet describes itself as a global medical technology leader with a comprehensive portfolio focused on mobility and health improvement.

🤖 The company leverages data analytics and artificial intelligence through its integrated digital and robotic technologies.

🌍 Zimmer Biomet operates in 25+ countries and generates sales in over 100 countries globally.

📈 The company highlights its legacy of 90+ years of trusted leadership and expertise in the medical technology sector.

🔗 Investors can find more information about the product portfolio and operations at www.zimmerbiomet.com.

Bullish Signals
  • ZBH announces $0.24 quarterly dividend for Q2 2026.
  • Global medical tech leader maximizing mobility and health.
  • Leverages AI and robotics to transform patient experience.
  • 90+ years of trusted leadership delivering quality solutions.
  • Operates in 25+ countries with sales in 100+.
Risk Factors
  • No negative aspects or risks identified for ZBH.
Bullish Signals
  • Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) announced a quarterly cash dividend of $0.24 per share for the second quarter of 2026, payable on or about July 31, 2026.
  • The company is recognized as a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
  • Zimmer Biomet leverages innovative products and integrated digital and robotic technologies that utilize data analytics and artificial intelligence to transform the patient experience.
  • With over 90 years of trusted leadership, the company is positioned to deliver high-quality solutions to patients and providers worldwide.
  • The company operates in 25+ countries with sales reaching 100+ countries, demonstrating a strong global footprint.
Risk Factors
  • The article contains no negative aspects or risks for Zimmer Biomet Holdings, Inc. (ZBH); it solely reports a positive dividend announcement and corporate growth metrics.
Bullish +70

Why Zimmer Biomet (ZBH) Stock Is Up Today

📈 Zimmer Biomet shares rose nearly 5% after raising buyback guidance to $1 billion for FY2026.

💹 Stock remains up 4.6% despite cooling, though it trades 22.8% below its yearly high.

🏛️ Interest rate cut optimism from Fed comments fueled broader market relief and recent gains.

📈 Zimmer Biomet shares jumped 4.9% after announcing an increase in share repurchase expectations for fiscal year 2026.

💰 The company plans to buy back up to $1 billion of common stock, a $250 million increase from its prior assumption.

🔄 This action utilizes an existing $1.5 billion share repurchase authorization authorized since February 2026.

📉 A share buyback reduces the number of shares available, which can increase the value of remaining shares and signal management confidence.

💹 After the initial pop, shares cooled to $83.20 but remain up 4.6% from the previous close.

📊 Zimmer Biomet's shares have been relatively stable with only 3 moves greater than 5% over the last year.

🗣️ The company's stock is down 7.6% since the beginning of the year and trades 22.8% below its 52-week high.

⏳ Investors who bought $1,000 worth of shares five years ago would currently hold approximately $508.04 worth of stock.

🐦 Historical volatility shows a previous significant gain of 3.4% six months ago due to Federal Reserve rate cut optimism.

🏛️ New York Fed President John Williams' recent comments increased the probability of an interest rate cut from 39% to over 73%.

🤖 The market rally following Fed remarks provided relief amid concerns over high valuations in AI-related stocks.

Bullish Signals
  • Zimmer Biomet increased share repurchase expectations by $250M for fiscal year 2026.
  • Enhanced buyback authorization signals management's confidence in undervalued stock.
  • Shares jumped 4.9% following announcement, showing positive market reception.
  • Stock trades at $83.20, just 22.8% below its 52-week high of $107.71.
  • Shares remained up 4.6% after cooling down, indicating sustained positive sentiment.
Risk Factors
  • Zimmer Biomet down 22.8% from $107.71 52-week high.
  • Limited bullish momentum despite buyback news as of August 2025.
Bullish Signals
  • Zimmer Biomet increased its share repurchase expectations for fiscal year 2026 by $250 million, now planning to buy back up to $1 billion of common stock.
  • This enhanced share buyback authorization signals management's confidence that the stock is undervalued and aims to increase the value of remaining shares.
  • Shares jumped 4.9% in the afternoon session following the announcement, demonstrating positive market reception to the capital allocation strategy.
  • The company is trading at $83.20 per share, which is only 22.8% below its 52-week high of $107.71, suggesting significant upside potential for investors.
  • Following the announcement, shares cooled down but remained up 4.6% from the previous close, indicating sustained positive sentiment.
Risk Factors
  • Zimmer Biomet has fallen 22.8% from its 52-week high of $107.71 as of August 2025, suggesting limited bullish momentum despite the buyback news.
Bullish +75

Zimmer Biomet discloses executive pay and double-digit increase for its median employee

📊 2025 revenue hit $8.23 billion, up 7% driven by Paragon and Monogram acquisitions.

💰 CEO Ivan Tornos earned $16.1M with heavy stock awards and aircraft perks.

✈️ Executives received significant pay, including cash bonuses for Noor and Thornal joining from other firms.

🚀 CFO Upadhyay departed to Incyte, prompting promotion of interim CFO Paul Stellato.

⚖️ Median employee pay rose double-digits while leaders maintain strong stock-based compensation alignment.

📊 Zimmer Biomet reported $8.23 billion in 2025 revenue, a 7% increase from the prior year, driven partly by acquisitions including Paragon 28 and Monogram Technologies.

💰 CEO Ivan Tornos received $16.1 million in total compensation for 2025, representing a 7% increase over the previous year's $15 million.

🎁 Tornos' pay package consisted of $1.3 million in salary, $12 million in stock awards, $2.4 million in performance bonuses, and over $400k in other perks including corporate aircraft usage.

👥 SVP Jehanzeb Noor was paid $7.8 million for 2025, a figure converted from Swiss Francs to USD using an average exchange rate of 1.2043.

🚀 Noor joined in March after previously leading Trivium's Europe, Africa, and Asia regions, receiving significant cash bonuses to replace forfeited payments from his previous role.

💵 CFO Suketu Upadhyay earned $6.2 million in 2025 but departed the company on April 28, 2026, to join biotech firm Incyte as its new CFO.

🔄 Paul Stellato was promoted to interim CFO while the board searches for a permanent successor following Upadhyay's departure.

🌎 Global Business and Americas President Kevin Thornal received $6.2 million in compensation, including $5.3 million in stock awards, after joining from Globus Medical-owned Nervo Corp.

⚖️ EMEA President Wilfred van Zuilen saw a 17% pay rise to $4.1 million for 2025, with his compensation package including a corporate apartment and car allowance valued at over $100k combined.

📈 The company's median employee experienced a double-digit increase in pay, aligning with broader disclosures required by the U.S. SEC for top executives.

🏆 Zimmer Biomet ranks as the 18th-largest medical device company globally based on 2024 revenue of $7.68 billion according to Medtech Big 100 data.

🤝 Strategic acquisitions in 2025 included Paragon 28 for foot and ankle expansion and Monogram Technologies to bolster the robotics portfolio with AI capabilities.

🧠 Executives like Noor and Thornal bring significant international experience, having previously led major regions or managed independent medical device firms before joining.

💸 A substantial portion of executive compensation at Zimmer Biomet is tied to stock awards, reinforcing alignment between leadership interests and long-term shareholder value.

✈️ Perks such as corporate aircraft usage, deferred compensation matching, and tax assistance contribute significantly to the total "other compensation" categories for senior leaders.

Bullish Signals
  • Zimmer Biomet reported 2025 revenue of $8.23 billion.
  • Strong 7% year-over-year growth in 2025 revenue.
  • $1.3 billion Paragon 28 acquisition expanded foot and ankle segment.
  • AI-driven robotics company Monogram Technologies acquired in 2025.
  • CEO Ivan Tornos total compensation reached $16.1 million.
  • SVP Jehanzeb Noor joined with $1.1 million cash bonus.
  • EMEA President Wilfred van Zuilen compensation rose 17%.
  • Ranked as world's 18th-largest medical device company.
Risk Factors
  • CEO compensation rose despite only 7% revenue growth.
  • CFO departure creates retention risk and knowledge drain.
  • Substantial perks like a $178,842 corporate jet questioned by investors.
  • High overhead spending reduces potential R&D or growth investments.
  • $1.3B acquisitions carry integration risks and impairment concerns.
Bullish Signals
  • Zimmer Biomet reported 2025 revenue of $8.23 billion, representing a strong 7% year-over-year growth from the prior year.
  • The company successfully expanded its footprint with the $1.3 billion acquisition of Paragon 28 in April 2025 to enhance its foot and ankle segment.
  • Zimmer Biomet further strengthened its portfolio by acquiring AI-driven robotics company Monogram Technologies in 2025.
  • CEO Ivan Tornos received a total compensation package of $16.1 million for 2025, a 7% increase from the previous year, signaling confidence in performance.
  • SVP and Chief Strategy Officer Jehanzeb Noor was recruited with an attractive package including a one-time $1.1 million cash bonus to help retain top talent.
  • EMEA Group President Wilfred van Zuilen saw a significant 17% increase in his total compensation for 2025 compared to the prior year.
  • The company is ranked as the world's 18th-largest medical device company based on 2024 revenue, highlighting its strong market position.
Risk Factors
  • CEO Ivan Tornos received $1.3 million in salary and $12 million in stock awards, raising questions about whether executive compensation is aligned more with shareholder dilution than performance given the company's reported revenue increase was only 7%.
  • The departure of former CFO Suketu Upadhyay on April 28, 2026, to join biotech rival Incyte represents a significant retention risk and potential knowledge drain as Zimmer Biomet searches for a permanent successor, currently led by an interim CFO.
  • Executive compensation packages include substantial non-business perks such as corporate aircraft usage totaling $178,842 for CEO Ivan Tornos and $38,857 for former CFO Suketu Upadhyay, which may be viewed skeptically by investors focusing on operational efficiency.
  • Zimmer Biomet paid Wilfred van Zuilen a $67,449 corporate paid apartment allowance, highlighting significant overhead spending that could detract from R&D or growth investments in the competitive medical device sector.
  • The company acquired two entities in 2025, Paragon 28 for $1.3 billion and AI-driven robotics company Monogram Technologies, creating integration risks and potential goodwill impairment concerns if these acquisitions do not deliver expected synergies quickly enough.
Bullish +75

Zimmer Biomet increases planned share repurchase to up to $1B by end of 2026

📈 Zimmer Biomet raises remaining buyback to $1 billion for fiscal 2026.

💰 Adjusted EPS guidance increased to $8.40–$8.55 with stable sales growth forecast.

🦴 New launches include G7 hip implants and a curved nail system.

📈 Zimmer Biomet is increasing its planned share repurchase by $250 million to reach up to $1 billion for the remainder of fiscal 2026.

💼 This increase falls under an existing $1.5 billion authorization approved by the board in February with no changes to size or terms.

📊 The company has already executed $250 million in repurchases during the first quarter of fiscal 2026.

⚖️ Repurchases will occur via open market purchases or structured agreements depending on market conditions, stock price, and capital availability.

👤 Zimmer Biomet recently appointed a new CFO as part of its ongoing executive team updates.

🦴 Key product launches include a new implant for the G7 hip line, a curved nail system, and a new foot and ankle platform.

📉 Sales guidance for 2026 remains between 2.5% and 4.5% revenue growth.

💰 Adjusted EPS guidance was raised to $8.40–$8.55 for fiscal 2026 from the previous range of $8.30–$8.45.

📍 The company is headquartered in Warsaw, Indiana, and operates within the orthopedic medical device sector.

📅 This announcement was released on May 12, 2026, following the first-quarter earnings report.

Bullish Signals
  • Zimmer Biomet raises buyback target to $1B by end-2026.
  • Adjusted EPS guidance increased to $8.40–$8.55 for 2026.
  • Strategic moves include new CFO and product innovations in hip, nail, and foot lines.
  • Company completed $250M share repurchases as of fiscal 2026 Q1.
Risk Factors
  • Relies on existing $1.5B authorization; no new capital sought.
  • Execution uncertain due to market conditions and price volatility.
  • Only $250M bought back in Q1 2026 vs $1B target.
  • Modest revenue growth forecasted between 2.5% and 4.5%.
  • Narrow 1.6% EPS expansion suggests subdued operating performance.
Bullish Signals
  • Zimmer Biomet has increased its planned share repurchase to up to $1 billion by end of 2026, a $250 million increase from prior assumptions, signaling strong management confidence and return of capital to shareholders.
  • The company's adjusted EPS guidance for 2026 was raised to $8.40–8.55, up from the previous range of $8.30–8.45, indicating positive performance outlook.
  • Recent strategic highlights include the appointment of a new CFO and significant product innovations, including a new implant to the G7 hip line, a new curved nail system, and a new foot and ankle platform.
  • Zimmer Biomet has already completed $250 million in share repurchases during fiscal 2026 as of its first-quarter earnings report, demonstrating active capital deployment.
Risk Factors
  • The company relies on its existing $1.5 billion share repurchase authorization approved in February for this increased buyback program, indicating no new capital authorization has been sought by the board.
  • Management explicitly states that timing and amounts of repurchases depend on market conditions, stock price, and capital availability, introducing significant uncertainty regarding the actual execution of the planned $1 billion spend.
  • Despite the buyback announcement, Zimmer Biomet only reports $250 million in share repurchases thus far during fiscal 2026, which is approximately one-fifth of the increased annual target as of the first quarter.
  • The company's sales guidance for 2026 remains modest, forecasting revenue growth between 2.5% and 4.5%, suggesting limited expected upside from core operations to fuel aggressive capital returns.
  • While adjusted EPS guidance was slightly raised to $8.40–8.55, the narrow 1.6% expansion suggests subdued expectations for operating performance in this fiscal year.
Somewhat Bullish +50

Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End

🚀 Zimmer Biomet raised 2026 buyback volume to up to $1 billion (+$250M).

✅ Executed under existing $1.5B authorization via open market or structured agreements.

⚠️ Management warns of M&A, integration, and macroeconomic risks affecting financial outcomes.

🚀 Zimmer Biomet Holdings (NYSE/SIX: ZBH) has increased its expected share repurchase volume for fiscal 2026 to up to $1 billion.

💰 This represents a $250 million increase from the company's previous assumption regarding buybacks.

✅ The new target is being executed under the existing $1.5 billion authorization approved by the Board in February 2026.

🔄 Management maintains that there are no changes to the size, duration, or terms of the original share repurchase program.

💹 Repurchases will be conducted via open market purchases or structured agreements with third parties depending on conditions.

⚖️ Actual buyback timing and amounts will depend on market conditions, stock price, capital availability, and alternative investment uses.

🏥 Zimmer Biomet is a global medical technology leader focused on mobility and health through digital and robotic innovations.

🌍 The company operates with a legacy of 90+ years and maintains presence in over 25 countries for operations and 100+ for sales.

⚠️ The press release includes standard forward-looking statements regarding financial guidance and macro pressures.

⚠️ Management cites various risks including competition, pricing pressures, supply chain disruptions, cyberattacks, and regulatory impacts.

📉 Potential headwinds include challenges with product rationalization, restructuring execution, and integration of acquired businesses.

💸 The company warns that actual benefits from acquisitions may not be realized within expected time periods or fully at all.

⚠️ Risks also extend to management attention due to M&A activities and potential disruptions from enterprise system updates.

Bullish Signals
  • Increased share repurchase expectations to $1 billion for FY 2026.
  • Utilizing existing $1.5 billion authorization shows strong financial confidence.
  • Global medical leader with over 90 years of trusted history.
  • Operates in over 25 countries with sales reaching over 100.
Risk Factors
  • Buybacks face timing uncertainty due to market conditions and capital availability.
  • Execution delays possible from variable market factors and capital constraints.
  • Pricing pressures, competition, and tech shifts threaten future results.
  • Product rationalization and acquisition failures could harm anticipated benefits.
  • Restructuring plans risk unplanned delays, disruptions, and unexpected expenses.
  • Acquired businesses may fail to integrate or meet benefit timelines.
  • Limited supplier dependence creates disruption risks for manufacturing supplies.
  • Cyberattacks and IT failures pose significant system breach risks.
  • Healthcare reforms may negatively impact operations via lower reimbursements.
  • High debt burdens threaten ability to service or refinance obligations.
Bullish Signals
  • Zimmer Biomet increased its share repurchase expectations to up to $1 billion for fiscal year 2026, representing a $250 million increase from the prior assumption.
  • The company will utilize its existing $1.5 billion share repurchase authorization, demonstrating strong confidence in its financial position and commitment to returning value to shareholders.
  • As a global medical technology leader with over 90 years of trusted leadership, Zimmer Biomet is positioned to deliver high-quality solutions through an innovative portfolio of products and digital technologies.
  • Zimmer Biomet operates in over 25 countries with sales reaching more than 100 countries, highlighting its robust global market presence.
Risk Factors
  • The company may repurchase shares depending on market conditions, stock price, capital availability, and alternative uses of capital, introducing significant uncertainty regarding the timing and actual amount of buybacks.
  • All share repurchases are subject to a variety of considerations including market conditions and capital availability, which could lead to execution delays or failure to meet repurchase expectations.
  • The press release includes numerous forward-looking risks such as pricing pressures, competition, dependence on new product development, and technological advances that could impact future results.
  • Risks include challenges relating to the rationalization of products, shifts in product category or regional sales mix, and potential failure to realize anticipated benefits from acquisitions.
  • The company faces risks related to its ability to successfully execute restructuring plans and product portfolio rationalization, which could lead to unplanned delays, disruptions, and expenses.
  • There is a risk that acquired businesses will not be integrated successfully or that the expected benefits from transactions will not be realized within the expected time period.
  • Dependence on a limited number of suppliers for key raw materials poses a disruption risk, particularly regarding supplies used in manufacturing or sterilizing products.
  • Significant risks include breaches or failures of information technology systems due to cyberattacks, unauthorized access, or theft.
  • The outcome of government investigations and the impact of healthcare reform, including cost containment measures and reductions in reimbursement levels, could negatively affect operations.
  • Substantial indebtedness poses a risk to the company's ability to service debt obligations and refinance amounts outstanding on favorable terms.
Slightly Bullish +25

Investors Can Find Comfort In Zimmer Biomet Holdings' (NYSE:ZBH) Earnings Quality

💸 Unusual $286m items reduced last twelve-month statutory profits significantly.

📈 EPS growth has been impressive over the past three years.

⚠️ Investors should note two specific warning signs highlighted in the article.

🔮 One-off expenses suggest potential future profit improvement soon.

📉 Zimmer Biomet Holdings' (NYSE:ZBH) most recent earnings report showed disappointing profit numbers for shareholders.

⚖️ Despite weak statutory profits, the article argues that the overall quality of the income statement remains optimistic.

💸 Statutory profit over the last twelve months was reduced by US$286m due to unusual items affecting the bottom line.

🔮 These unusual expenses are likely one-off in nature, suggesting potential profit improvement if they do not repeat soon.

📈 Analyst forecasts and an interactive graph are available to view future profitability expectations for the company.

💰 Earnings per share have grown at an extremely impressive rate over the last three years.

⚠️ The article notes two specific warning signs for Zimmer Biomet Holdings that investors should pay attention to.

📊 Beyond profit, other key metrics like margins, forecast growth, return on investment, and insider buying are suggested for deeper analysis.

🛑 Simply Wall St's editorial team states their analysis is based on historical data and analyst forecasts, not financial advice.

Bullish Signals
  • US$286m one-off expenses may boost next year's profits.
  • EPS has grown impressively for three years.
Risk Factors
  • Zimmer Biomet's recent earnings report disappointed shareholders.
  • US$286 million statutory profit reduced by unusual items.
  • Two warning signs identified for Zimmer Biomet Holdings.
  • Mixed sentiment despite high return on equity.
Bullish Signals
  • Zimmer Biomet Holdings' statutory profit was reduced by US$286m due to unusual items, but these are expected to be one-off expenses that will likely improve profits over the coming year.
  • Earnings per share have grown at an extremely impressive rate over the last three years, demonstrating strong underlying business growth despite recent soft numbers.
Risk Factors
  • The most recent earnings report from Zimmer Biomet Holdings was disappointing for shareholders.
  • Statutory profit was reduced by US$286 million due to unusual items over the last twelve months.
  • There are currently two warning signs identified for Zimmer Biomet Holdings that require attention.
  • The article notes that high return on equity is sometimes viewed differently, indicating mixed market sentiment.
Bullish +60

5 Revealing Analyst Questions From Zimmer Biomet’s Q1 Earnings Call

📈 Q1 revenue reached $2.09B with 9.3% growth and EPS beat estimates by 12.2%.

⚠️ Operating margins expanded while international growth slowed due to distributor consolidation.

🤖 Future growth relies on Oxford partial knee adoption and Monogram robotic system rollout.

💸 Full-year EPS guidance was raised, though margins face pressure from tariffs.

📉 Stock price fell despite strong earnings amidst ongoing sales force transitions.

📈 Zimmer Biomet reported Q1 2026 revenue of $2.09 billion, beating analyst estimates by 0.9% and showing 9.3% year-over-year growth.

💰 Adjusted EPS came in at $2.09 per share, significantly surpassing the consensus estimate of $1.86 by a 12.2% beat.

🚀 Operating margins expanded to 17.9%, up from 15.3% in the prior year's quarter.

🔧 CEO Ivan Tornos highlighted a greater than 20% increase in partial knee sales driven by the Oxford Partial Cementless Knee.

⚠️ Management noted operational disruptions and tempered momentum due to brand rationalization, account losses, and ongoing U.S. sales force transitions.

📉 Full-year Adjusted EPS guidance was raised to $8.48 at the midpoint, representing a 1.2% increase from previous expectations.

🌍 International revenue growth slowed compared to prior periods due to tougher comparisons, distributor consolidation, and order timing issues.

🛠 Analysts are closely monitoring the pace of U.S. sales force transformation, particularly regarding productivity gains and account retention rates.

🤖 The adoption and clinical rollout of the Monogram robotic system remain a key area of focus for future growth and technology platform adoption.

💸 CFO Suky Upadhyay clarified that underlying gross margin performance was stable, though modest lower margins are expected for the full year absent one-time tariff benefits.

❓ Stifel analyst Frederick Wise questioned why guidance wasn't raised more substantially given the strong quarterly results.

🏦 JPMorgan analyst Robert Marcus inquired about the sustainability of gross margins and the impact of one-time items like tariff-related benefits.

💼 TD Cowen's Matthew Blackman sought specifics on productivity improvements resulting from the ongoing sales force restructuring.

📉 Goldman Sachs' David Roman questioned the slower international growth rate, which management attributes to external distribution changes.

📉 Zimmer Biomet shares traded down from $92.59 to $82.40 following the earnings report despite the positive financial results.

👀 StockStory analysts plan to watch for stabilization in international operations and progress on new technology platforms in upcoming quarters.

📊 The article notes that management remains cautious about full-year potential due to the transitional nature of the current year.

Bullish Signals
  • Q1 2026 revenue hit $2.09B, beating estimates with 9.3% YoY growth.
  • Adjusted EPS beat expectations by 12.2%, reaching $2.09 vs $1.86 estimate.
  • Adjusted EBITDA surged to $840.5M, a 40.3% margin expansion.
  • Management raised full-year Adjusted EPS guidance to $8.48 at the midpoint.
  • Operating margins expanded to 17.9%, up from 15.3% last year.
  • Constant Currency Revenue grew 6.8% YoY, surpassing prior 2.3% growth.
  • Partial knee sales rose >20% driven by Oxford Cementless Knee success.
Risk Factors
  • Stock fell 11% despite beating earnings due to market skepticism.
  • Management kept full-year guidance unchanged citing ongoing operational changes.
  • Underlying margins expected to be lower after one-time tariff boost.
  • International growth slowed by distributor consolidation and order timing issues.
  • Future success depends on sales force transformation and tech adoption.
Bullish Signals
  • Zimmer Biomet's first quarter of 2026 revenue reached $2.09 billion, beating Wall Street estimates of $2.07 billion with a year-on-year growth of 9.3%.
  • The company reported an impressive Adjusted EPS beat of 12.2%, reaching $2.09 against the expected $1.86.
  • Zimmer Biomet significantly outperformed on Adjusted EBITDA, recording $840.5 million versus analyst expectations of $633 million, with a 40.3% margin.
  • Management raised its full-year Adjusted EPS guidance to $8.48 at the midpoint, representing a proactive 1.2% increase.
  • Operating margins expanded to 17.9%, up from 15.3% in the same quarter last year, demonstrating improved operational efficiency.
  • Constant Currency Revenue grew 6.8% year-over-year, showing underlying business strength that was not present in the prior period's 2.3% growth.
  • Partial knee sales increased by greater than 20%, driven specifically by strong performance from the Oxford Partial Cementless Knee product line.
Risk Factors
  • Despite beating earnings expectations, Zimmer Biomet's stock price fell significantly to $82.40 from $92.59 just before the report, indicating market skepticism about sustainability.
  • Management explicitly cited ongoing sales force and market changes as reasons for 'prudence' in guidance, leading them to not raise full-year Adjusted EPS guidance more substantially despite a strong quarter.
  • CFO Suky Upadhyay clarified that while Q1 benefited from a one-time tariff-related boost, the underlying performance faces expectations for 'modestly lower gross margin for the year'.
  • CEO Ivan Tornos acknowledged operational disruptions and 'tempered positive momentum' caused by brand rationalization and account losses during the transformation period.
  • International growth remains slower than desired due to distributor consolidation and order timing issues, requiring stabilization before mid-single-digit growth can be realized in the second half.
  • Future performance hinges on critical execution risks including the pace of US sales force transformation impact on productivity and account retention, as well as the adoption of new technology platforms like Monogram robotic system.
Neutral 0

Zimmer Biomet Buzz Grows Across NYSE Composite Trend

⚠️ Text is a promotional landing page lacking financial data.

📉 No specific earnings or Zimmer Biomet performance updates included.

🔒 Content functions as a subscription prompt rather than news.

🛑 The provided text is a promotional landing page rather than an actual news article about Zimmer Biomet, containing no specific financial data, earnings figures, or detailed updates.

⚠️ The content references various other companies like Stellantis and Weyerhaeuser but does not include any substantive information regarding Zimmer Biomet's performance.

🔒 The text functions as a paywall or subscription prompt for Kalkine Media, requesting user contact details and consent for marketing calls instead of reporting on market trends.

Bullish Signals
  • Healthcare demand remains strong for medical device companies like Zimmer Biomet, indicating a favorable market environment.
  • The article highlights the balance between operational strength and external factors, suggesting resilience in core business areas.
Risk Factors
  • The article header references Zimmer Biomet (ZBH) but the visible content only discusses Stellantis, Weyerhaeuser, and WisdomTree, offering no specific negative data for ZBH itself.
  • Market sentiment reflects leadership changes and evolving expectations, suggesting potential instability or uncertainty surrounding the company's management direction.
  • Healthcare demand remains strong, which may mask underlying issues if operational challenges arise in response to 'evolving expectations' that are not detailed here.
Bullish +75

Zimmer Biomet Announces First Quarter 2026 Financial Results

📈 Q1 net sales rose 9.3% to $2.087 billion with strong cash flow generation.

💰 EPS surged 34.1% year-over-year, prompting raised full-year guidance for adjusted metrics.

🤝 Leadership highlighted solid progress, launched new robotic systems, and honored ethical innovations.

📈 First quarter net sales reached $2.087 billion, marking a 9.3% increase reported versus the prior year period.

💰 Diluted earnings per share were $1.22, representing a 34.1% increase compared to the same period last year.

📉 Adjusted diluted earnings per share stood at $2.09, reflecting a 15.5% year-over-year growth.

💵 The company generated $359.4 million in operating cash flow and $245.9 million in free cash flow for the quarter.

🤝 Chairman and CEO Ivan Tornos stated the business is showing solid strategic, operational, and financial progress.

🚀 Management raised its full-year 2026 guidance for adjusted EPS and free cash flow expectations based on current momentum.

💸 The company completed $250 million in share repurchases during the first quarter of fiscal 2026.

👩‍⚕️ Dr. Jonathan M. Vigdorchik was appointed as Chief Science, Technology and Medical Affairs Officer to oversee global technology portfolios including AI and robotics.

🤖 Clinical enrollment opened for mBôs, an autonomous robotic total knee arthroplasty system acquired from Monogram Technologies in India.

🦴 The G7 Acetabular System completed its first case following FDA 510(k) clearance in February 2026 for hip replacement surgeries.

🎤 Zimmer Biomet launched ROSA Knee with OptimiZe and showcased innovations at the 2026 American Academy of Orthopaedic Surgeons meeting.

🏆 The company was named to FORTUNE's list of America's Most Innovative Companies and Ethisphere's list of World's Most Ethical Companies.

🦵 The Phantom Curved TTC Nail System was launched by Paragon 28 to support hindfoot fusion procedures.

📊 Revenue growth included contributions from geography segments such as North America, Europe, Asia Pacific, Latin America, and Emerging Markets.

🏷️ Product category performance covered Technology & Data, Bone Cement, Surgical tools, and implants including Sports Medicine and Trauma.

⚠️ The guidance update excludes the projected impact of the Paragon 28 acquisition for the one-year anniversary period.

📞 An investor conference call was held today at 8:30 a.m. ET via webcast on the company's Investor Relations website.

🔢 Revenue increases were driven by constant currency growth of 6.8% and organic constant currency growth of 2.9%.

Bullish Signals
  • Zimmer Biomet Q1 net sales rose 9.3% to $2.087 billion.
  • Adjusted diluted EPS grew 15.5% to $2.09 in the quarter.
  • Company generated $359.4M operating cash flow and $245.9M free cash flow.
  • Management raised full-year 2026 adjusted EPS and free cash flow guidance.
  • Zimmer Biomet completed $250 million in share repurchases during Q1.
Bullish Signals
  • Zimmer Biomet reported first quarter net sales of $2.087 billion, representing a strong 9.3% increase year-over-year.
  • Adjusted diluted earnings per share reached $2.09, marking a significant 15.5% growth over the prior year period.
  • The company generated substantial operating cash flow of $359.4 million and free cash flow of $245.9 million in the first quarter.
  • Management raised full-year 2026 adjusted EPS and free cash flow guidance, demonstrating confidence in sustained operational momentum.
  • Zimmer Biomet completed $250 million in share repurchases during the first quarter, reflecting strength in their capital allocation strategy.
  • The company was named to FORTUNE's 2026 list of America's Most Innovative Companies and Ethisphere's World's Most Ethical Companies for the second consecutive year.
  • The autonomous robotic total knee arthroplasty system mBôs completed enrollment in its multi-center clinical study in India, a key milestone for future commercialization.
  • The G7® Acetabular System achieved FDA 510(k) clearance in February 2026 and successfully completed its first case using the next-generation implant.
  • The full commercial launch of ROSA® Knee with OptimiZe was showcased at the 2026 AAOS annual meeting, highlighting successful product innovation.
  • Paragon 28 subsidiary launched the Phantom® Curved TTC Nail System to support hindfoot fusion procedures, expanding its orthopedic portfolio.
Risk Factors
  • The article contains no negative aspects or risks; it exclusively reports strong financial growth, rising earnings guidance, product launches, and positive strategic milestones.
  • Consequently, a JSON array of negative points cannot be generated as per the requirement to extract only pessimistic elements from the provided text.
Somewhat Bullish +50

10 Stocks Reeling From Huge Losses

📉 Wall Street closed negative as Nasdaq led a decline across major indices.

💸 Zimmer Biomet stock hit a 13-year low after its CFO departed despite strong earnings.

🧬 Qiagen nosedived due to lowered growth outlooks caused by Middle East tensions.

🏢 Alexandria Real Estate fell sharply following a downgrade and reduced occupancy forecasts.

⚽ Sportradar dropped to a 52-week low after missing revenue and profit estimates.

📉 Ten stocks declined sharply on Tuesday as Wall Street's major indices finished in the red, with the Nasdaq leading the drop at 0.90 percent.

🏥 Zimmer Biomet Holdings Inc. (NYSE:ZBH) fell to a new 13-year low and dropped 10.53% despite strong Q1 earnings due to the immediate departure of its CFO.

👔 The CFO, Suketu Upadhyay, stepped down after seven years to pursue another opportunity, with Chief Accounting Officer Paul Stellato serving as interim replacement.

📈 Zimmer Biomet reported a 30.8% net income jump to $238.1 million and a 9.3% sales increase to $2.09 billion in the first quarter.

🧬 Qiagen NV (NYSE:QGEN) nosedived 10.7% to a seven-year low amid a lowered growth outlook caused by Middle East tensions impacting its QuantiFERON blood test sales.

📉 Qiagen revised its full-year 2026 net sales growth outlook down to 1% to 2% and decreased Adjusted EPS guidance to $2.43 from $2.50.

🏢 Alexandria Real Estate Equities Inc. (NYSE:ARE) shed 11.30% after a bearish downgrade from BNP Paribas, which cut its price target by 13.6% to $44.

📉 Although Alexandria posted strong net profits of $358.87 million in Q1, occupancy rates dropped to 87.7% and the company lowered its full-year occupancy outlook.

⚽ Sportradar Group (NASDAQ:SRAD) fell to a new 52-week low after missing revenue estimates and receiving a price target downgrade from Guggenheim Securities.

📉 Sportradar revenues reached €347 million, exceeding year-on-year growth but missing analyst expectations due to player-friendly outcomes and foreign currency headwinds.

💸 The company's adjusted EBITDA of €66 million also missed estimates of €68 million, while it reported an attributable net loss of €6.286 million compared to a prior profit.

🏗️ The article notes that the list of ten worst-performing stocks only includes companies with at least $2 billion in market capitalization and 5 million shares in trading volume.

Bullish Signals
  • Zimmer Biomet reported a strong earnings performance in the first quarter, with net income jumping 30.8% to $238.1 million versus $182 million in the same period last year.
  • Net sales increased by 9.3% to $2.09 billion from $1.909 billion year-on-year, demonstrating robust revenue growth despite broader market declines.
  • The company appointed Paul Stellato as interim CFO to provide continuity and steady direction during the transition, ensuring management stability.
  • Chairman and CEO Ivan Tornos expressed confidence in the leadership team's ability to execute strategy and deliver on commitments during this period.
Risk Factors
  • Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) plummeted to a new 13-year low, dropping 10.53 percent, despite reporting strong Q1 earnings, due to investor concerns over the immediate departure of its CFO Suketu Upadhyay.
  • The CFO's sudden resignation has forced Zimmer Biomet to rely on interim replacement Paul Stellato while searching for a permanent candidate, creating uncertainty about leadership stability and strategic continuity.
  • Shares of Alexandria Real Estate Equities Inc. (NYSE:ARE) fell to a nearly 17-year low, shedding over 11 percent, as the stock was downgraded by BNP Paribas following a decline in occupancy rates from 91.7% to 87.7%.
  • Alexandria Real Estate lowered its full-year occupancy rate outlook to a range of 86.2% to 87.8%, missing previous guidance, and increased its projected net operating loss margin to between 8.5% and 10.5%. The company's stock dropped nearly 17 percent, shedding 11.30 percent.
  • Shares of Sportradar (NASDAQ:SRAD) crashed to a new 52-week low, dropping over 14 percent after missing revenue expectations due to unfavorable outcomes and headwinds.
  • Sportradar reported a full-year net loss of €6.286 million, reversing a profit of €24.2 million from the prior year, which contributed significantly to its sharp stock decline despite some revenue growth.
  • The broader market downturn saw all three major indices finish in the red, with the Nasdaq leading the drop by 0.90 percent and the S&P 500 declining 0.49 percent.
  • Investors are reacting negatively to corporate news headlines, causing a sharp sell-off across ten major stocks including Zimmer Biomet, Alexandria Real Estate, and Sportradar.
Bullish +65

Should You Buy Zimmer Biomet Holdings, Inc. (NYSE:ZBH) For Its Upcoming Dividend? - simplywall.st

📅 Buy before March 31st for April 30th dividend.

💰 $0.24/share dividend yields 1.1% on $89.15 price.

📈 EPS grew 18% annually over past five years.

💵 Conservative payout: 27% of earnings, 17% of cash flow.

⚠️ Two specific warning signs exist for this stock.

📅 Investors must buy shares before March 31st to qualify for the April 30th dividend payment.

💰 The upcoming dividend is US$0.24 per share, resulting in a trailing yield of 1.1% on the current price of US$89.15.

📈 Earnings per share have grown rapidly at an average rate of 18% annually over the past five years.

💵 The dividend payout ratio is conservative at 27% of earnings and 17% of free cash flow, indicating sustainability.

🔄 The company retains over half of its earnings for reinvestment into business growth initiatives.

⚠️ The article notes the presence of two specific warning signs regarding the stock that investors should be aware of.

Bullish Signals
  • Dividend fully covered by net income and free cash flow.
  • Earnings per share grew 18% annually over last five years.
  • Conservative payout ratio of only 27% allows future increases.
  • Retains over half earnings for reinvestment and growth.
  • Adequate balance sheet supports consistent dividend payments.
Risk Factors
  • Two warning signs identified for Zimmer Biomet Holdings.
  • Low trailing dividend yield of 1.1%.
Bullish Signals
  • The dividend is fully covered by both net income and free cash flow, reducing the risk of a cut.
  • Earnings per share have grown at an impressive average rate of 18% per annum over the last five years.
  • The company maintains a conservative payout ratio of only 27% of earnings, leaving ample room for future increases.
  • Zimmer Biomet retains more than half of its earnings within the business, signaling a strong focus on reinvestment and growth.
  • The stock possesses an adequate balance sheet while simultaneously paying a consistent dividend.
Risk Factors
  • The article explicitly states that Zimmer Biomet Holdings currently faces two warning signs that investors should be aware of.
  • The trailing dividend yield is relatively low at 1.1%, which may not appeal to high-yield seekers compared to other sectors.
Somewhat Bullish +45

Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?

📈 Strong fundamentals: ZBH beats estimates quarterly with high earnings yield versus industry.

💸 Robust cash flow: Generated $1.172B free cash flow while navigating tariff challenges.

⚠️ Elevated debt: High leverage noted at 37.2% debt-to-capital ratio as year ends.

📉 Laggard performance: Stock dropped 22% recently despite outperforming the broader industry.

🦵 Growth drivers: Knee revenue up 6% due to cementless implant adoption success.

📈 Zimmer Biomet (ZBH) is well-positioned for growth, supported by its People and Culture, Operational Excellence, and Innovation pillars.

📉 The stock has dropped 22% over the past year compared to a 18.3% S&P 500 gain, despite outperforming the industry.

💰 The company holds a market cap of $17.18 billion with an attractive 9.6% earnings yield versus the industry average of 2.6%.

📊 ZBH has surpassed earnings estimates in four consecutive trailing quarters with an average surprise of 2.53%.

👔 Leadership strengthening includes the appointment of Kevin Thornal as group president for Global Businesses and the Americas.

💸 The company generated $1.172 billion in free cash flow in 2025 while navigating tariffs and integrating acquisitions.

🤖 Monogram Technologies was acquired to expand robotics offerings, with commercialization expected alongside Zimmer Biomet implants in early 2027.

🦵 U.S. knee business revenues grew 6% year-over-year in Q4 2025, driven by strong adoption of cementless offerings like Persona OsseoTi.

🎯 Cementless implant penetration reached approximately 35% for the Persona OsseoTi as of late 2025, with a long-term goal to increase further.

🌐 Organic constant currency revenue grew 5.4% in Q4 2025, split between U.S. (5.7%) and international (5%) growth.

⚠️ The company exits 2025 with high leverage, holding $7.52 billion in debt against $591 million in cash, resulting in a 37.2% debt-to-capital ratio.

⚔️ The medical device market remains intensely competitive with rivals including Stryker, Johnson & Johnson, Medtronic, and Smith & Nephew.

📅 Analyst consensus estimates for ZBH project $8.40 EPS and $8.55 billion revenue for 2026, representing a 3.9% revenue increase.

📉 Alternative top-ranked medical stocks include Globus Medical (Zacks #1), Phibro Animal Health (Zacks #1), and Intuitive Surgical (Zacks #2).

Bullish Signals
  • Zimmer Biomet is well-positioned for growth with strong performance in its U.S. knee business, which grew revenues by 6% year-over-year in the fourth quarter of 2025.
  • The company generated $1.172 billion in free cash flow during 2025, reflecting improved cash generation and disciplined capital allocation despite tariff headwinds and acquisitions.
  • Zimmer Biomet surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 2.53%, indicating consistent operational strength.
  • The adoption of cementless offerings continues to accelerate, with the Persona OsseoTi knee reaching approximately 35% penetration of U.S. total knee implants by the end of 2025.
  • Recent acquisition of Monogram Technologies adds surgeon-guided semi and fully autonomous robotic technologies expected to begin commercialization with Zimmer Biomet implants in early 2027.
  • Organic constant currency revenue growth of 5.4% was delivered in Q4 2025, supported by healthy end markets and improved procedure volumes globally.
  • The company completed a strategic focus on innovation and diversification, contributing to portfolio strength through new product waves like ROSA Knee with OptimiZe.
  • As of the fourth quarter of 2025, Zimmer Biomet held $591 million in cash and cash equivalents, providing financial flexibility for future investments.
Risk Factors
  • The stock has dropped 22% in the past year compared to the industry's 20.5% fall and is underperforming significantly against the S&P 500 composite which saw 18.3% growth.
  • The company carries a highly leveraged balance sheet with total debt of $7.52 billion and only $591 million in cash and equivalents as of Q4 2025.
  • The debt-to-capital ratio stands at 37.2%, which is considered moderately high and poses a risk for financial flexibility during periods of market stress.
  • Continuing pricing pressure in the global musculoskeletal market, despite reported stability, could threaten future revenue growth if volumes do not fully compensate.
  • The competitive landscape remains intensely fierce with major players like Stryker, Johnson & Johnson's DePuy, Smith & Nephew, and Medtronic requiring constant new product innovation or acquisitions to maintain market share.
  • Analyst consensus estimates for 2026 have remained stagnant at $8.40 EPS over the past 30 days, suggesting limited growth expectations from Wall Street.
  • Revenue growth projections for 2026 are modest at just a 3.9% increase, reflecting cautious near-term visibility despite recent operational improvements.